Y Combinator Will Give You $1 Million to Try to Cure Aging
The famed startup incubator Y Combinator put out a call for companies that want to increase human longevity and “health span.”
Who they want: Founders with new ideas for treating old-age diseases like Alzheimer’s, “but we will also consider more radical anti-aging schemes,” YC president Sam Altman told MIT Technology Review.
Why longevity? Efforts to stop old age don’t actually get funded much. “My sense is that economic incentives of drugs companies are screwed up” says Altman. “I don’t think we have enough people saying, How can we make a lot of people a lot heathier?”
The deal: Longevity startups get $500,000 to $1 million in exchange for a 20 percent stake, lab space, and advice (quite a bit more than the $120,000 software companies get if they’re picked for the incubator. But hey, biology is more expensive). They will travel to San Francisco to join the next three-month “class" of startups, which starts in June.
Big bio returns? Y Combinator started accepting biology companies in 2014. One of them, Ginkgo, has gone on to raise hundreds of millions more to fund its organism-hacking business. As for others, Altman says he’s not worried about getting his money back: “You could make a pill that added two years to a person’s life that would be a $100 billion company.”
Deep Dive
Biotechnology and health
OpenAI has created an AI model for longevity science
The company is making a foray into scientific discovery with an AI built to help manufacture stem cells.
Digital twins of human organs are here. They’re set to transform medical treatment.
The models can be used to plan surgeries and in the future could be used to help trial new drugs.
Mice with two dads have been created using CRISPR
It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.
Stem-cell therapies that work: 10 Breakthrough Technologies 2025
After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.